Hospitals

Akron Children’s to get greater access to cystic fibrosis drugs, clinical trials

A special designation by the Cystic Fibrosis Foundation will give Akron Children’s Hospital access to clinic trials and the latest drugs and nutritional supplements, the hospital announced this week.

AKRON, Ohio — A special designation by the Cystic Fibrosis Foundation will give Akron Children’s Hospital access to clinic trials, and the latest drugs and nutritional supplements, the hospital announced this week.

The foundation named the Lewis H. Walker M.D. Cystic Fibrosis Center at Akron Children’s a Therapeutic Development Network site. The network includes more than 70 other institutions. Nationwide Children’s Hospital in Columbus and Rainbow Babies & Children’s Hospital were among the first network members.

Among the goals of the network is to help move drugs faster into Phase 3 studies, which are the final phase of clinical trials before a new drug application is made.

Akron Children’s has 220 cystic fibrosis patients. Between 2006 and 2007, the number of Akron Children’s patients involved in cystic fibrosis-related clinical trials doubled from 38 to 76, according to the hospital.